– AG-348 Is Well-Tolerated and Demonstrates Clinically Relevant, Rapid and Sustained Hemoglobin Increases in 25 of 52 Patients Overall – – New Data Show Improvements in Hemolysis Associated Parameters Indicate Positive Impact on Disease Biology – – Program on Track to Enter Global Pivotal Development in First Half of 2018 – MADRID, Spain, June 24, 2017 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) presented updated data from its wholly owned Pyruvate Kinase-R (PKR) activator demonstrating the potential for the first disease-modifying treatment for patients with pyruvate kinase (PK) deficiency at the 22nd Congress of the European Hematology Association (EHA). PK […]